.png)
CardiacSense
CE/FDA-cleared medical watch — continuous A-Fib/arrhythmia detection (PPG/ECG) + multi-vital monitoring for RPM/telemedicine
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
CardiacSense is positioned as a clinically oriented medical wearable company focused on continuous arrhythmia and blood-pressure monitoring, with clear emphasis on FDA/CE-cleared differentiation and IP-backed sensing technology. The company appears to be pursuing B2B/clinical adoption and remote monitoring use cases rather than broad consumer wearables.
Efficiency Ratio
The company shows strong technical output relative to its small reported headcount, but commercially visible traction appears moderate, suggesting a product-development-efficient organization that is still scaling market penetration.
Evidence Signals
Website and company materials state the wearable is FDA cleared and CE marked for continuous monitoring of arrhythmias and blood pressure.
Company describes a strong IP portfolio spanning optics, mechanics, and signal processing, indicating patent-backed technical differentiation.
LinkedIn lists the company as privately held with 11-50 employees and about 7,309 followers, showing a modest but real social footprint.
ZoomInfo estimates revenue at under $5 million, implying limited but existing commercial activity.
PitchBook and Wikipedia both indicate a roughly 40-employee organization, consistent with a small medtech startup profile.
DevelopmentAid reports a contract from a tier-1 wristwatch manufacturer to develop an algorithm for continuous wrist-based blood pressure monitoring.
The company participated in the EU H2020/CORDIS project on continuous heart arrhythmia and blood pressure monitoring, indicating external validation and R&D collaboration.
- About
- Israeli medical-device company (CardiacSense Ltd.; HQ Caesarea, Israel — North Industrial Park; founded 2009; ~11-50 staff) that makes a CE- and FDA-cleared 'medical watch' for long-term continuous vital-sign monitoring and real-time arrhythmia detection on the wrist. Using proprietary PPG and/or ECG sensors, it continuously detects atrial fibrillation and other arrhythmias (company-reported 99.2% sensitivity/specificity), and also tracks respiration rate (to monitor CHF/COPD patients), SpO2, heart-rate variability, skin temperature, sleep-apnea and activity, with a physician portal; a cuff-less absolute blood-pressure capability has been in development. Positioned for Remote Patient Monitoring (RPM), Chronic Care Management (CCM) and telemedicine. Defense relevance: continuous casualty/remote-vitals monitoring fits the C12-03 monitoring cluster (peer to Biobeat, Neteera, Oxitone and Cnoga), but CardiacSense is civilian-first with no defense credential.
- Tags
- #wearable #arrhythmia #atrialfibrillation #cufflessbp #vitalsigns #ecg #ppg #monitoring #fda #dualuse